TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters 
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Nvidia Invests $1 Billion in Naver as South Korea AI Data Center Expansion Gains Momentum 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says 
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors 
A couple of drug industry trade groups sued the Trump administration separately in federal courts in Maryland and California, challenging new US rules to lower drug prices.
The plaintiffs were filed by the Pharmaceutical Research and Manufacturers of America (PhRMA), a pharmaceutical industry trade group, and biotechnology industry trade organizations.
The rule being challenged, which will take effect on Jan. 1, would tie payments for some drugs made by Medicare, a US government insurance program, to the lowest price paid by some countries.
According to the administration, the move could save taxpayers and patients $85 billion over seven years.
The PhRMA claims the rule change is illegal because it is too far-reaching to qualify as a pilot.
Steve Ubl, PhRMA’s CEO, said the rules could not be categorized as it impacts the entire country and implicates 90 percent of spending with no control group.
The Association of Community Cancer (ACC), which joined PhRMA in the suit, noted that lower reimbursements for drugs could put cancer treatment centers out of business, as many rely heavily on Medicare.
Both suits claim that the appropriate process in coming up with the rules was not followed, as it failed to collect feedback from stakeholders before its announcement.
